Exscientia

Exscientia plc announced two abstracts for oral and poster presentation, as well as the closing keynote to be delivered at the Society for Laboratory…

Exscientia plc announced that Sumitomo Pharma Co., Ltd. (‘Sumitomo Pharma’) plans to initiate a Phase 1 clinical study of DSP-2342 in the United…

Effort aligns MD Anderson’s drug development expertise with Exscientia’s AI-driven patient-first precision medicine and drug discovery platforms…

Fast and accurate generative AI design of novel antibodies extends Exscientia's capabilities beyond small molecules Sequencing paired human…

Exscientia, ETH Zurich, the Medical University of Vienna, and the Center for Molecular Medicine (CeMM) announced a new publication in Blood Cancer…

* Collaborative efforts aim to accelerate drug discovery and improve clinical success * Agreement to utilize Exscientia’s AI-based capabilities and…

Following a highly successful year and several drug discovery milestones using its flagship AI platform, Exscientia is pleased to welcome Andrew…

Facilities in The Schrödinger Building to bring together AI experts and biologists  Exscientia, the innovative company at the forefront of…

Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce the appointment of…